Oppenheimer Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Raises Target Price to $164
Oppenheimer Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Eli Lilly and Co. is startled, novo-nordisk a/s saves the day! The market prospects for weight loss drugs still tempt many players.
The weight loss drug market still has a broad prospect, with most institutions predicting that the market size will reach the trillion-dollar level by the end of this decade.
10 Health Care Stocks With Whale Alerts In Today's Session
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Viking Therapeutics to Present Data From Phase 2b VOYAGE Study of VK2809 in Patients With Biopsy-Confirmed NASH/MASH at the 75th Liver Meeting 2024
71688427 : It may go to 51